Veracyte Inc VCYT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026
-
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
-
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
-
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
-
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
-
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
-
Veracyte to Participate in Upcoming Investor Conferences
-
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
Trading Information
- Previous Close Price
- $46.15
- Day Range
- $46.21–47.80
- 52-Week Range
- $26.61–60.91
- Bid/Ask
- $46.91 / $47.77
- Shares Outstanding
- 80.39M
- Market Cap
- $3.80B
- Volume/Avg
- 821,473 / 1M
Key Statistics
- Price/Earnings (Normalized)
- 25.76
- Price/Sales
- 6.85
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Growth
- Total Number of Employees
- 755
- Website
- https://www.veracyte.com
Valuation
|
Metric
|
VCYT
|
|---|---|
Price/Earnings (Normalized) | 25.76 |
Price/Book Value | 2.73 |
Price/Sales | 6.85 |
Price/Cash Flow | 21.80 |
Price/Earnings
VCYT
Financial Strength
|
Metric
|
VCYT
|
|---|---|
Quick Ratio | 8.60 |
Current Ratio | 9.16 |
Interest Coverage | — |
Quick Ratio
VCYT
Profitability
|
Metric
|
VCYT
|
|---|---|
Return on Assets (Normalized) | 12.12% |
Return on Equity (Normalized) | 13.09% |
Return on Invested Capital (Normalized) | 11.63% |
Return on Assets
VCYT
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|M^HW^tL! | LOCK|c@^ | $220B | |||
| Danaher Corp
DHR
| LOCK|<#x@%Pwv | LOCK|%? | $144B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|!@<^r>pW | LOCK|^^$ | $46B | |||
| Agilent Technologies Inc
A
| LOCK|GP$w%Pv! | LOCK|<^ | $41B | |||
| Waters Corp
WAT
| LOCK|&@tw>Y& | LOCK|W< | $40B | |||
| IQVIA Holdings Inc
IQV
| LOCK|mR!$Rt | LOCK|&tDv! | $39B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|Y!#&l$f@ | LOCK|#>jd? | $29B | |||
| Illumina Inc
ILMN
| LOCK|$GLlJ!F | LOCK|?>dC# | $28B | |||
| Quest Diagnostics Inc
DGX
| LOCK|!?Wm>t | LOCK|ynv^t | $26B | |||
| Labcorp Holdings Inc
LH
| LOCK|y$ZK#># | LOCK|&gZ?p | $26B |
United States